
## Laura Godfrey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5373748/publications.pdf Version: 2024-02-01



LALIDA CODEDEV

#	Article	IF	CITATIONS
1	H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. Leukemia, 2021, 35, 90-106.	7.2	35
2	Chromatin accessibility governs the differential response of cancer and TÂcells to arginine starvation. Cell Reports, 2021, 35, 109101.	6.4	20
3	BET inhibition disrupts transcription but retains enhancer-promoter contact. Nature Communications, 2021, 12, 223.	12.8	84
4	Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. Blood, 2019, 134, 1059-1071.	1.4	62
5	DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation. Nature Communications, 2019, 10, 2803.	12.8	99
6	MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27Âacetylation. Experimental Hematology, 2017, 47, 64-75.	0.4	25
7	MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. Cell Reports, 2017, 18, 482-495.	6.4	69
8	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports, 2015, 13, 2715-2727.	6.4	118